Methods for Reprogramming and Gene Editing Cells
Summary
The USPTO published patent application US20260108554A1 on April 23, 2026, filed on May 1, 2023 under application number 18861162. The application names seven inventors — Matthew ANGEL, Christopher ROHDE, Ian HAY, Ismet Caglar TANRIKULU, Tae Yun KIM, Abigail BLATCHFORD, and Mackenzie PARMENTER — and covers improved methods for reprogramming and gene editing cells, including manufacturing lymphoid and myeloid lineage cell populations. CPC classifications span cell therapy (A61K), proteins (C07K), and gene editing technologies (C12N).
“The present disclosure provides improved methods for reprogramming and gene editing cells, including manufacturing a population of cells comprising cells of the lymphoid lineage and/or cells of the myeloid lineage.”
About this source
USPTO classification A61K covers pharmaceutical preparations: formulations, dosage forms, combination therapies, delivery systems, and the vehicles that carry active ingredients. Every newly published application in A61K lands in this feed, around 245 a month. Applications publish 18 months after filing, so this feed reveals what pharma formulators at major sponsors and generics were working on in the prior year and a half. Watch this if you compete in drug formulation, file freedom-to-operate analyses, scout competitive drug products before clinical readouts, or follow novel delivery platforms like nanoparticles, lipid carriers, and long-acting injectables.
What changed
The USPTO published patent application US20260108554A1, a new patent filing covering methods for reprogramming and gene editing cells to produce lymphoid and myeloid lineage cell populations. The application names seven specific inventors and includes CPC classifications spanning cell therapy, proteins, and gene editing technologies.
For biotechnology and pharmaceutical companies engaged in cell therapy development, gene editing platforms, or immune cell manufacturing, this patent application signals potential freedom-to-operate considerations in the lymphoid and myeloid cell reprogramming space. Competitors developing similar cell manufacturing processes should review the claims upon issuance to assess any overlap with existing or planned programs.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
METHODS FOR REPROGRAMMING AND GENE EDITING CELLS
Application US20260108554A1 Kind: A1 Apr 23, 2026
Inventors
Matthew ANGEL, Christopher ROHDE, Ian HAY, Ismet Caglar TANRIKULU, Tae Yun KIM, Abigail BLATCHFORD, Mackenzie PARMENTER
Abstract
The present disclosure provides improved methods for reprogramming and gene editing cells, including manufacturing a population of cells comprising cells of the lymphoid lineage and/or cells of the myeloid lineage.
CPC Classifications
A61K 35/15 A61K 40/31 C07K 14/5418 C07K 14/5428 C07K 14/5434 C07K 14/5443 C07K 14/55 C07K 14/70539 C12N 9/222 C12N 15/111 C12N 15/625 C12N 15/88 C12N 15/907 C07K 2319/02 C12N 2310/20 C12N 2510/00
Filing Date
2023-05-01
Application No.
18861162
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.